Gilead and arcus announce anti-tigit domvanalimab plus zimberelimab and chemotherapy exceeded one year of median progression-free survival as a first-line treatment for upper gi cancers

Foster city, calif. & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced longer-term efficacy and safety results from arm a1 of the phase 2 edge-gastric study. these updated data show consistent objective response rate (orr) and provide mature progression-free survival (pfs) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper gi cancers). t.
RCUS Ratings Summary
RCUS Quant Ranking